Cumberland Pharmaceuticals has announced a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of Vibativ (telavancin)...
The FDA on 21 June 2013 expanded the approved use of the antibiotic Vibativ (telavancin) from Theravance, to treat patients...
Astellas and Theravance have received marketing authorisation from the European Commission for Vibativ (telavancin hydrochloride) for nosocomial pneumonia caused by...
The Advisory Committee (AIDAC) of the FDA has voted 9-6 that data, from Theravance relative to Vibativ (telavancin), failed to...
Theravance Biopharma, Inc. announced the sale of its proprietary antibiotic, Vibativ (telavancin), to Cumberland Pharmaceuticals, Inc. a specialty pharmaceutical company...
Merck Inc announced that the FDA has approved a supplemental New Drug Application (sNDA) for Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: